TC Biopharm (Holdings) PLC (TCBPY) Prix

TC BioPharm (Holdings) plc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T (GD-T) cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia (AML). The Company is conducting two investigator-initiated clinical trials for its unmodified GD-T cell product line - phase IIb/III pivotal trial in treatment of AML using its allogeneic CryoTC technology to provide frozen product to clinics worldwide. Its lead product candidate, OmnImmune is an unmodified allogeneic GD-T cell product, being initially used for the treatment of AML. Its pre-clinical stage program is focused on developing CAR-modified allogeneic GD-T cell products targeting solid and hematological indications. It has an Israeli patent and Japanese patent applications covering the method of preparing and using GD-T cells in the allogeneic treatment of subjects suffering from viral, fungal and protozoal infections or cancer.